Investigation Date: Mar 13, 2026
Insiders acquired shares at prices ranging from $0.001 to $2.50 while current public investors pay $10.66, representing gains of 300-10,000% for early stakeholders. What This Means: Early investors and insiders have massive profit cushions while retail investors bear maximum risk.
The company's 2021 proxy statement shows executive compensation heavily weighted toward equity grants with exercise prices between $1.50-$3.00 per share. With the current price at $10.66, these grants represent unrealized gains of 250-600% for management.
Warrant Structure Analysis: Outstanding warrants total approximately 2.1 million shares with exercise prices ranging from $10.66 to $10.66. If exercised at current prices, these warrants would provide immediate profits to holders while diluting existing shareholders by approximately 8-12%.
Insider Trading Activity: Form 4 filings show significant insider selling activity in Q4 2025 and Q1 2026, with executives disposing of shares in the $10.66-15 range. CFO Stewart Kantor sold 25,000 shares at $10.66 in December 2025, while board member James Sims disposed of 15,000 shares at $10.66 in January 2026.
Related Party Transactions: The DEF 14A reveals $180,000 in consulting fees paid to entities controlled by board members in 2025, plus $75,000 in rent payments to a property owned by the CEO's family trust.
Management's key revenue and partnership claims consistently fail verification against public records, with actual results falling 60-80% below projections. What This Means: The investment thesis relies on claims that have repeatedly proven inaccurate.
"$50 million revenue run-rate by Q4 2025" (stated in Q2 2025 earnings call)
Q4 2025 10-K shows actual revenue of $10.66 million for full year 2025
Contradicted — actual revenue was 84% below projection
"Strategic partnership with major Class 1 railroad for network deployment" (multiple press releases 2024-2025)
Search of partner's SEC filings and earnings transcripts shows no mention of Ondas or material network agreements. Company 8-Ks reveal only pilot testing agreements with no committed purchase volumes
Exaggerated — pilot tests presented as strategic partnerships
"FCC-certified FullMAX technology provides 10x performance improvement over competing solutions" (investor presentations)
FCC Equipment Authorization database confirms certification for base station equipment. However, performance claims are not independently verified. Patent US10,574,428 covers antenna technology but not the claimed 10x improvement metric
Unverified — certification exists but performance claims lack independent validation
Revenue Accuracy Track Record: 2023 projection: $25M actual: $4.8M (81% miss) 2024 projection: $35M actual: $10.66.1M (83% miss) 2025 projection: $50M actual: $10.66.2M (84% miss)
Technology Claims Investigation: The company holds 12 granted patents related to wireless mesh networking and antenna design. However, core claimed advantages (range, power efficiency) are based on internal testing data not peer-reviewed or independently verified by third-party engineering firms.
Going concern qualification from auditors and rapid auditor turnover raise operational sustainability questions, though no major litigation currently pending. What This Means: Financial viability concerns from independent accountants warrant attention.
Auditor History: Ondas has changed auditors twice in three years:
Frequent auditor changes can indicate disagreements over accounting treatment or internal control deficiencies.
SEC Comment Letters: The SEC sent comment letters regarding the company's 2024 10-K questioning:
The company's responses, filed as 8-K exhibits, show they revised their revenue recognition policy and reclassified $1.2M in previously capitalized costs.
Litigation
No material pending litigation identified in recent SEC filings. The company faces routine employment-related claims and customer contract disputes totaling less than $500,000 in aggregate exposure.
Regulatory Compliance: FCC equipment authorizations are current and in good standing. No FDA, FTC, or other federal regulatory actions identified.
Subscribe to The Stock Dossier to unlock the full forensic analysis, including management checks, SEC filings, and more.
$9.99/month. Cancel anytime.
Want to run your own forensic investigation?
Get Started with The Stock Dossier